NCT06151249
Not yet recruiting
Phase 2
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Ability of Meritup Oral Liquid to Reduce Fatigue in Patients With Metastatic Breast Cancer Receiving Chemotherapy
ConditionsMetastatic Breast Cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Metastatic Breast Cancer
- Sponsor
- Chung Shan Medical University
- Enrollment
- 32
- Primary Endpoint
- Changes in fatigue scores
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.
Detailed Description
The study population designed to be enrolled is patients with histologically and/or cytologically confirmed breast cancer with clinical evidence of recurrent or progressive metastatic disease and at least completed 3 cycle chemotherapy regimen who have evidence of fatigue.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female patients over 20years old and under 80 years old.
- •Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2), These 3 indicators are all negative.
- •After at least 3 cycles of chemotherapy.
- •Sign the subject Informed Consent Form (ICF).
Exclusion Criteria
- •Have received other clinical studies within 3 weeks
- •Any uncontrollable infection
- •History of lupus erythematosus, rheumatoid arthritis, ankylosing spondylosis, scleroderma or multiple sclerosis
- •History of cancer cells that have metastasized to the brain
- •Currently receiving a mixture of three or more types of cytotoxic chemotherapy drugs
- •Currently using anti-fatigue treatments, including psychostimulants, acupuncture, etc. Note: Antidepressants are used for treatment to relieve fatigue (such as depression or hot flashes) is allowed,
- •Need to use long-acting sustained-release pain narcotic analgesics
- •Uncontrollable nausea, vomiting or other symptoms that will hinder the ability to speak about the test product
- •Any other serious illness/history that would limit the patient's ability to receive study treatment, as determined by the researcher evaluate
- •Lactation, pregnancy or planning pregnancy
Outcomes
Primary Outcomes
Changes in fatigue scores
Time Frame: one months
Changes in fatigue scores using the Functional Assessment of Chronic Illness Treatment (FACIT)-Fatigue subscale after 9 weeks of combined chemotherapy treatment
Secondary Outcomes
- Blood test(one month)
Similar Trials
Terminated
Phase 2
Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease FatigueMetastatic Breast CancerFatigueNCT02645175Meriyana Bio Inc.3
Completed
Phase 3
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in KoreanAcute MigraineNCT04218162IlDong Pharmaceutical Co Ltd294
Completed
Phase 2
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced ConstipationOpioid Induced ConstipationNCT01459926Theravance Biopharma217
Terminated
Phase 2
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT03517566Novartis Pharmaceuticals293
Completed
Phase 1
A Study of Aleglitazar in Combination With Aspirin in Healthy VolunteersHealthy VolunteerNCT01188304Hoffmann-La Roche44